share_log

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $28

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $28

高盛对Agios Pharmicals保持中立,将目标股价下调至28美元
Benzinga ·  2023/11/03 10:18

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $32 to $28.

高盛分析师萨尔文·里希特维持Agios Pharmicals(纳斯达克股票代码:AGIO)为中性,并将目标股价从32美元下调至28美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发